petrelintide

News

Zealand hit as Roche-partnered obesity drug disappoints

Shares in Zealand lost a third of their value today, after the biotech reported phase 2 data with Roche-partnered weight-loss therapy petrelintide.

News

Roche builds in obesity with $5.3bn Zealand licensing deal

Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma.

News

David Kendall, chief medical officer at Zealand Pharma

Zealand Pharma rakes in $1bn in funding for obesity drugs

Fresh from reporting encouraging results with its obesity drug candidate petrelintide, Zealand Pharma has raised an impressive $1 billion from a new share offering.

Zealand hit as Roche-partnered obesity drug disappoints

Roche builds in obesity with $5.3bn Zealand licensing deal

Zealand Pharma rakes in $1bn in funding for obesity drugs

OpenBind unveils its first AI model for drug discovery

Discover a new era of healthcare panel engagement: Grounded ...

Editor's Picks